FDA blocks Hospira Symbiq touchscreen-enabled infusion pump imports

Wed, 11/14/2012 - 2:46pm
Mass Device

The FDA prohibits Hospira from importing any new Symbiq infusion pumps systems after the medical device company recalled the devices over a touchscreen issue.

Hospira logo

Infusion pump maker Hospira (NYSE:HSP) found itself in deepening water after the FDA decided to prohibit the company from importing any new lots of its Symbiq touchscreen-enabled infusion pumps.

The pumps, which are imported from the company's manufacturing facility in Costa Rica, underwent a Class I recall late last month over touchscreen issues that the FDA said may result in delayed or inaccurate medication delivery that could injure patients.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.